These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 23220480)
21. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787 [TBL] [Abstract][Full Text] [Related]
22. Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition. Doggett EA; Zhao J; Mork CN; Hu D; Nichols RJ J Neurochem; 2012 Jan; 120(1):37-45. PubMed ID: 22004453 [TBL] [Abstract][Full Text] [Related]
23. [Advance of the study on LRRK2 gene in Parkinson's disease]. Zhang Y; Chen S Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525 [TBL] [Abstract][Full Text] [Related]
24. LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5. Shanley MR; Hawley D; Leung S; Zaidi NF; Dave R; Schlosser KA; Bandopadhyay R; Gerber SA; Liu M Biochemistry; 2015 Aug; 54(33):5198-208. PubMed ID: 26268594 [TBL] [Abstract][Full Text] [Related]
25. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223 [TBL] [Abstract][Full Text] [Related]
26. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease. Greggio E Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865 [TBL] [Abstract][Full Text] [Related]
27. [Pathogenesis of Parkinson's disease through LRRK2 mutation]. Ohta E; Obata F Seikagaku; 2014 Feb; 86(1):92-7. PubMed ID: 24693706 [No Abstract] [Full Text] [Related]
28. Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration? Gillardon F J Neurochem; 2009 Sep; 110(5):1514-22. PubMed ID: 19545277 [TBL] [Abstract][Full Text] [Related]
29. Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families. Ohta E; Hasegawa K; Gasser T; Obata F Neurosci Lett; 2007 Apr; 417(1):21-3. PubMed ID: 17395370 [TBL] [Abstract][Full Text] [Related]
30. Leucine-rich repeat kinase 2 regulates tau phosphorylation through direct activation of glycogen synthase kinase-3β. Kawakami F; Shimada N; Ohta E; Kagiya G; Kawashima R; Maekawa T; Maruyama H; Ichikawa T FEBS J; 2014 Jan; 281(1):3-13. PubMed ID: 24165324 [TBL] [Abstract][Full Text] [Related]
35. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768 [TBL] [Abstract][Full Text] [Related]
36. G2019S LRRK2 mutant fibroblasts from Parkinson's disease patients show increased sensitivity to neurotoxin 1-methyl-4-phenylpyridinium dependent of autophagy. Yakhine-Diop SM; Bravo-San Pedro JM; Gómez-Sánchez R; Pizarro-Estrella E; Rodríguez-Arribas M; Climent V; Aiastui A; López de Munain A; Fuentes JM; González-Polo RA Toxicology; 2014 Oct; 324():1-9. PubMed ID: 25017139 [TBL] [Abstract][Full Text] [Related]
37. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. Gloeckner CJ; Schumacher A; Boldt K; Ueffing M J Neurochem; 2009 May; 109(4):959-68. PubMed ID: 19302196 [TBL] [Abstract][Full Text] [Related]
38. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048 [TBL] [Abstract][Full Text] [Related]
39. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Deng H; Le W; Davidson AL; Xie W; Jankovic J Neurosci Lett; 2006 Oct; 407(2):97-100. PubMed ID: 16939701 [TBL] [Abstract][Full Text] [Related]
40. Parkinson-Related LRRK2 Mutation R1628P Enables Cdk5 Phosphorylation of LRRK2 and Upregulates Its Kinase Activity. Shu Y; Ming J; Zhang P; Wang Q; Jiao F; Tian B PLoS One; 2016; 11(3):e0149739. PubMed ID: 26930193 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]